Director
 |
Scott E. McNeil, PhD Dr. McNeil serves as the Director of the Nanotechnology Characterization Laboratory (NCL) for Leidos Biomedical Research and Frederick National Laboratory for Cancer Research, where he coordinates preclinical characterization of nanotech cancer therapeutics and diagnostics. |
Pharmacology & Toxicology
 |
Stephan T. Stern, PhD, DABT Dr. Stern is actively involved in applied nanomaterial research, and has published numerous articles on nanomaterial toxicology and pharmacokinetics in leading scientific journals. |
 |
David Stevens, PhD Dr. Stevens develops novel drug formulation strategies including micelle formulations and polymeric prodrugs for the improved delivery of small molecule chemotherapeutics. |
 |
Sarah Skoczen, MS Ms. Skoczen joined the NCL in September of 2005, as a Research Assistant. She is responsible for helping maintain human and animal primary and immortalized cells. |
 |
Kelsie Snapp, BS, MBA Kelsie’s role at the NCL involves working with bioanalytical assays and helping to develop methods for measuring nanoparticle drug release for the pharmacology and toxicology section. |
Immunology
 |
Marina A. Dobrovolskaia, PhD, MBA Dr. Dobrovolskaia is a Senior Principal Scientist and Head of the Immunology Section at the Nanotechnology Characterization Laboratory (NCL). |
 |
Barry Neun, BS Mr. Neun is the primary technician responsible for endotoxin and sterility pre-screening of all materials submitted to the NCL. |
 |
Timothy Potter, BS Mr. Potter is the primary tissue culture technician for the NCL, maintaining human and animal primary and immortalized cells. His duties include running a variety of cell-based toxicity and immunology assays and working closely with other NCL personnel in assay development. |
 |
Edward Cedrone, BS Mr. Cedrone’s main role at the NCL is assessing nanoparticle effects on immune cell function by conducting in vitro and in vivo cell-based immune assays. Edward brings a wealth of experience in cell and tissue culture from his previous employment at the Cell Biology Program of the American Type Culture Collection (ATCC) in Manassas, Virginia. |
Physicochemical Characterization
 |
Jeffrey D. Clogston, PhD Dr. Clogston joined the Nanotechnology Characterization Laboratory (NCL) as a Scientist in March 2006. In his position, Dr. Clogston conducts physico-chemical characterization and standardization of nanoparticles intended for cancer therapeutics and diagnostics. |
 |
Yingwen Hu Dr. Hu joined the Nanotechnology Characterization Laboratory (NCL) as a Scientist in July 2017. Her research focuses on the physicochemical characterization of nanoparticles using advanced analytical methods. |
 |
Alison Vermilya, MS Mrs. Vermilya assists in the physicochemical characterization of nanoparticles that are studied at the NCL, including transmission electron microscopy (TEM) imaging and size analysis, dynamic light scattering (DLS), and zeta potential measurements. |
Alliance Management
 |
Rachael M. Crist, PhD Dr. Crist is a Sr. Scientist in the NCL, in charge of Alliance Management opertaions. In this role, she coordinates research efforts across multiple disciplines to promote the clinical translation of novel nanotech therapeutics and diagnostics. |